8-K: PACS Group Reports Strong Q3 2025, Completes Restatement

PACS Group, Inc. announced robust third-quarter 2025 financial results, including a 31% revenue increase, and confirmed the completion of its financial statement restatement and Audit Committee investigation.

Summary

• Revenue for the third quarter of 2025 was $1.34 billion, marking a 31.0% increase over the prior year.
• Net income for Q3 2025 reached $52.3 million.
• Adjusted EBITDA for Q3 2025 was $131.5 million, and Adjusted EBITDAR was $226.6 million.
• Year-to-date 2025 revenue was $3.93 billion, an increase of 36.4% over the prior year period.
• Year-to-date 2025 net income was $131.7 million, with Adjusted EBITDA at $363.0 million and Adjusted EBITDAR at $646.2 million.
• Full-year 2024 revenue, including restated figures, was $4.09 billion, up 31.4% from 2023, with net income of $55.3 million and Adjusted EBITDA of $279.5 million.
• The company has completed the previously announced Restatement of its financial statements for Q1 2024 and Q2 2024, and is now current with its SEC filing obligations.
• The independent Audit Committee completed its investigation concerning allegations made in a short seller report and other identified matters.
• Cash provided by operations for the nine months ended September 30, 2025, was $407.6 million.
• Cash and cash equivalents increased to $355.7 million as of September 30, 2025, from $157.7 million as of December 31, 2024.
• 192 facilities, representing 68.6% of the skilled nursing portfolio, achieved a 4 or 5 star CMS Quality Measure Star rating.
• Mature facilities occupancy rate was 94.8%, significantly higher than the industry average of 79%.

Sentiment

Score: 8

Explanation: The company reported strong financial results with significant revenue and net income growth, successfully completed a major financial restatement and Audit Committee investigation, and provided positive full-year guidance. Operational metrics like mature facility occupancy are well above industry averages. While there were revenue reductions from the restatement and high legal costs, the resolution of these issues and strong underlying performance are highly positive.

Positives

• Strong revenue growth: Q3 2025 revenue increased by 31.0% to $1.34 billion, and YTD 2025 revenue grew by 36.4% to $3.93 billion.
• Significant increase in net income: Q3 2025 net income of $52.3 million, up from $16.2 million in Q3 2024; YTD 2025 net income of $131.7 million, up from $19.153 million in YTD 2024.
• Improved Adjusted EBITDA: Q3 2025 Adjusted EBITDA of $131.5 million, up from $49.1 million in Q3 2024; YTD 2025 Adjusted EBITDA of $363.0 million, up from $185.5 million in YTD 2024.
• Completion of financial statement restatement and current SEC filing obligations, resolving prior compliance issues.
• Completion of the Audit Committee investigation, reinforcing commitment to transparency, accountability, and strong governance.
• High operational performance with 68.6% of skilled nursing facilities achieving 4 or 5 star CMS Quality Measure Star ratings.
• Mature facilities occupancy rate of 94.8% significantly exceeds the industry average of 79%.
• Substantial cash provided by operations: $407.6 million for the nine months ended September 30, 2025.
• Increased cash and cash equivalents to $355.7 million as of September 30, 2025, from $157.7 million at December 31, 2024.
• Positive full-year 2025 guidance: Revenue expected between $5.25 billion and $5.35 billion, and Adjusted EBITDA between $480 million and $490 million.
• Expansion of portfolio to 320 healthcare operations across 17 states, with 51 facilities owned and 59 purchase options.

Negatives

• The restatement resulted in a $14.9 million reduction in revenue for the three-month period ended March 31, 2024, and a $46.1 million reduction for the three-month period ended June 30, 2024.
• Ramping facilities experienced a decrease in skilled nursing services revenue by 34.8% in Q3 2025 and 34.2% year-to-date 2025.
• Occupancy rate for ramping facilities significantly dropped from 93.9% in Q3 2024 to 86.1% in Q3 2025.
• Total skilled mix by revenue decreased from 50.5% in Q3 2024 to 48.0% in Q3 2025.
• Total skilled mix by nursing patient days decreased from 29.3% in Q3 2024 to 28.2% in Q3 2025.
• Legal and other costs related to the Audit Committee's independent investigation and other ongoing investigations amounted to $19.6 million in Q3 2025 and $66.5 million year-to-date 2025.

Risks

• Dependence on third-party payors, including adverse changes in patient acuity and payor mix, payment methodologies, and cost containment initiatives.
• Potential inability to obtain full reimbursement for services billed under consolidated billing or bundled payments.
• Exposure to increased labor costs, staffing shortages of nurses, nurse assistants, and other skilled personnel, and impacts from national labor unions.
• State or federal regulatory actions affecting healthcare services, facility construction, expansion, or acquisition.
• Ability to attract and retain patients and to compete effectively with other healthcare providers.
• Internal audits and reviews that may result in billing adjustments, repayments, fines, or other corrective actions.
• Ongoing and future investigations and litigation.
• Limitations and variability of insurance and self-insurance programs.
• Risks relating to the restatement of financial statements.
• A material weakness in internal control over financial reporting and risks related to remediation or the emergence of additional weaknesses.
• Failures to provide consistently high-quality care or employee conduct that adversely affects patient health, safety, or clinical treatment.
• Reliance on information technology and the risk that failures, inadequacies, or interruptions could disrupt operations.
• Reliance on internally calculated operational metrics that may be subject to measurement challenges or perceived inaccuracies.
• Ability to complete, integrate, and realize expected benefits from acquisitions or partnerships and potential liabilities or regulatory issues arising from such transactions.
• The disposition of underperforming or non-strategic operating subsidiaries and the revenue impact of such dispositions.
• Geographic concentration of facilities that exposes the company to local economic downturns, regulatory changes, or natural disasters.
• Risks associated with leased real property, including lease terminations, extensions, and special charges.
• Failure to generate sufficient cash flow to meet long-term debt, mortgage, and lease obligations and covenants, which could lead to defaults or loss of facilities.
• Ability to obtain additional capital on acceptable terms, or at all.
• Extensive and evolving legal and regulatory compliance obligations and the potential costs to achieve or maintain compliance.
• Substantial control of the company by founders, which may result in conflicts of interest or the appearance of conflicts.
• Status as a controlled company under NYSE rules and the governance implications of relying on applicable exemptions.

Future Outlook

PACS Group expects full-year 2025 revenue to be in the range of $5.25 billion to $5.35 billion and Adjusted EBITDA to be between $480 million and $490 million. The company plans to continue expanding its footprint through a balanced approach of leasing and acquiring real estate, actively evaluating opportunities for both high-performing and underperforming operations across multiple states.

Management Comments

• "Our strong third quarter and year-to-date results demonstrate the underlying strength of our business model and the relentless execution of our team to deliver on our mission." Jason Murray, CEO.
• "Our performance validates our core strengths our commitment to clinical and operational excellence, industry-leading talent and a strategy designed for sustainable growth." Jason Murray, CEO.
• "With the Restatement and Audit Committee investigation now complete, we are moving forward with a strong financial foundation, enhanced controls and an even stronger conviction in our ability to drive meaningful growth and create value for shareholders." Jason Murray, CEO.
• "Our third-quarter and year-to-date 2025 revenue growth reflects the operational excellence across our portfolio that continues to drive demand for our services." Mark Hancock, Interim CFO.
• "We remain confident that our locally-led, centrally-supported model, coupled with enhanced compliance and controls, will increase our ability to deliver high-touch, high-quality care to our patients and strengthen our communities." Mark Hancock, Interim CFO.

Industry Context

The post-acute healthcare sector continues to see demand, as evidenced by PACS Group's significant revenue growth and high occupancy rates in mature facilities. The company's focus on clinical and operational excellence, coupled with strategic expansion through acquisitions and leases, positions it to capitalize on ongoing demographic shifts and healthcare needs. The completion of the restatement and investigation also addresses a key concern that had been impacting investor confidence in the sector.

Comparison to Industry Standards

• Mature facilities occupancy rate of 94.8% significantly exceeds the reported industry average of 79%.
• The company's strategy of acquiring both high-performing and underperforming operations aligns with broader industry trends of consolidation and value creation in the fragmented post-acute care market.

Corporate Governance

Legal Proceedings

• The independent Audit Committee completed its investigation concerning allegations made in a short seller report against the Company and management, as well as other matters identified during the course of the investigation.
• Legal and other costs of $19.6 million in Q3 2025 and $66.5 million year-to-date 2025 were incurred associated with the Audit Committee's independent investigation and with other ongoing investigations.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, resolution of restatement and investigation, positive future outlook, and commitment to value creation.
• Patients/Residents: Continued commitment to providing high-quality care, evidenced by high CMS Quality Measure Star ratings and operational excellence.
• Employees: Continued growth and expansion suggest stable to growing employment opportunities. Management comments emphasize "industry-leading talent."
• Regulatory Authorities: Improved standing due to completion of restatement and compliance with SEC filing obligations, and implementation of Audit Committee recommendations.

Next Steps

• Execute strategy, deliver exceptional care, and build trust with stakeholders.
• Expand footprint through a balanced approach to leasing and acquiring real estate.
• Actively evaluate opportunities to acquire both high-performing and underperforming operations across multiple states.
• Continue to execute strategy to drive value for shareholders and the rest of the healthcare ecosystem.
• Implement recommendations from the Audit Committee investigation.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance with robust revenue and net income growth, significantly exceeding prior year figures. The successful completion of the financial restatement and the Audit Committee investigation removes significant overhangs and demonstrates a commitment to strong corporate governance and transparency. The positive full-year 2025 guidance, coupled with industry-leading operational metrics like mature facility occupancy, indicates strong underlying business health and future growth potential. While legal costs were high due to the investigation, their resolution paves the way for clearer future performance. The stock appears poised for appreciation given these strong fundamentals and the removal of prior uncertainties.

Keywords

post-acute healthcare, skilled nursing, SEC filing, financial results, earnings, restatement, Audit Committee investigation, occupancy rates, EBITDA, EBITDAR, healthcare operations, CMS Quality Measure, patient care, corporate governance